Novastep

Executive Summary

Novastep is a private medical device company founded in 2020 and headquartered in San Francisco, specializing in minimally invasive surgical solutions for foot and ankle conditions, particularly bunion correction. Its product portfolio includes instrument systems and implants designed to enhance procedural reproducibility and patient outcomes. The company operates in the growing digital health and medical devices space, targeting a common musculoskeletal issue with a less invasive approach. While Novastep has not disclosed funding or revenue details, its focus on innovation in a niche surgical segment positions it for potential adoption by podiatrists and orthopedic surgeons seeking improved techniques. Despite the promise of its technology, Novastep faces significant challenges typical of early-stage medtech firms: regulatory hurdles, clinical validation, and commercial scaling. The company has no publicly announced FDA approvals or clinical trials, and its stage remains unclear. However, if it successfully demonstrates safety and efficacy, it could capture a meaningful share of the bunion surgery market, which is estimated at several hundred thousand procedures annually in the U.S. alone. The company's low profile suggests it may still be in development or early commercialization, making it a high-risk, high-reward opportunity dependent on upcoming regulatory and clinical milestones.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for Next-Gen Bunion Implant40% success
• Q3 2026Series A or B Funding Round Announcement60% success